GSK (GSK) announced that the FDA has approved a prefilled syringe presentation of Shingrix for the prevention of shingles. The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a lyophilized antigen and a liquid adjuvant, which healthcare professionals combine prior to administering. The approval of the new presentation is based on data demonstrating technical comparability between the new and existing vaccine presentation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces US FDA approved prefilled syringe presentation of SHINGRIX
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- Sell Rating on GlaxoSmithKline Due to Concerns Over Blenrep’s Ocular Toxicity and Limited US Trial Applicability
- GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab
- GSK lower after FDA briefing documents for myeloma drug